Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


He P, Shen Y. Interruption of beta-catenin signaling reduces neurogenesis in Alzheimer's disease. J Neurosci. 2009 May 20;29(20):6545-57. PubMed Abstract

  
Comments on Paper and Primary News
  Primary News: Amyloid-β—Turning Neurogenesis Into Neurogenocide?

Comment by:  Nibaldo Inestrosa
Submitted 26 May 2009  |  Permalink Posted 26 May 2009

In this paper, He and Shen report that the renewal capacity of glial progenitor cells (GPCs) isolated from the superior temporal cortex of Alzheimer disease (AD) patients is reduced compared to that of cells from healthy controls and that this reduced neurogenesis capacity correlates with an increased GSK-3β activity and an increased phosphorylation of β-catenin. They also found that treating GPCs from healthy controls with aggregates of Aβ led to increased β-catenin phosphorylation and reduced neurogenesis. These findings suggest that Aβ-induced interruption of Wnt signaling contributes to the impairment of neurogenesis in AD patients.

Early in 2000, we proposed that a loss of the Wnt signaling was triggered by Aβ in AD (2). Later on we, and others, confirmed that Aβ induces an impairment of Wnt signaling function, indicating that a sustained loss of this pathway occurs during Aβ neurodegeneration (3). The reduction in neurogenesis in GPCs is accompanied by a decrease in the Wnt signaling function (1). This is entirely consistent with our studies, which indicate that a...  Read more


  Primary News: Amyloid-β—Turning Neurogenesis Into Neurogenocide?

Comment by:  Agata Copani
Submitted 28 May 2009  |  Permalink Posted 28 May 2009

This paper by He and Shen is of great interest for several reasons. The first is that the authors address the link between neurogenesis and Alzheimer disease (AD) by studying the cell fate of neural progenitors isolated from AD autopsy specimens. The second is that this study, unlike many others, is not focused on a specialized “neurogenic niche” of the adult brain but rather the cerebral cortex. This brings me to a third reason: the attention to the role of Wnt/β-catenin signaling in the fate specification of cortical multipotent progenitor cells. Wnt/β-catenin signaling is known to promote cell fate specification in the developing cortex (1), and it is also known to be impaired in AD (2,3).

He and Shen report that glial precursor cells (GPCs) isolated from AD cortices exhibit reduced differentiation toward neurons compared with GPCs from healthy controls. This phenotype is causally related to an increased GSK-3β activity with ensuing phosphorylation of β-catenin (i.e., β-catenin degradation). It is very nice that the authors demonstrate that in GPCs from APP23 transgenic...  Read more


  Primary News: Amyloid-β—Turning Neurogenesis Into Neurogenocide?

Comment by:  Michael Kahn, Agnes Lukaszewicz
Submitted 4 June 2009  |  Permalink Posted 4 June 2009

Editor's note: This comment contains a diagram which is also linked below in the text.

Alzheimer disease is principally characterized by a gradual and hierarchical decline in cognition, an impairment that correlates with accumulation of amyloid plaques and neurodegeneration in regions of the brain involved in higher cognitive function, such as the frontal cortex. The hippocampus represents a structure where neuroplasticity is maintained throughout life and is believed to be impaired in AD. This plasticity plays an important role in memory and response to injury. Despite extensive investigation, a mechanistic understanding of AD pathogenesis on hippocampal plasticity remains unclear. Unknown is whether hippocampal impairment is driven by cell-autonomous or non-cell autonomous mechanisms (or both). A negative correlation has been established between plaque formation and/or microglia-mediated neuroinflammation and hippocampal neurogenesis. Additionally, we have previously demonstrated that...  Read more

  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 

REAGENTS/MATERIAL:
ELISA: after gradient centrifugation for 60 min, cells were incubated with rabbit anti-cell-surface chondroitin sulfate proteoglycan, NG2 (Millipore Bioscience Research Reagents). For total Aβ ELISA, the capture antibody was monoclonal anti-Aβ (4G8) (Millipore Bioscience), and the detection antibody was biotinylated monoclonal anti-Aβ (6E10) (Signet Covance). Aβ40 and Aβ42 were measured with Aβ40 ELISA kits and Aβ42 ELISA kits (Biosource).
Immunofluorescence: The cells were immunostained with specific antibodies at 2, 7, or 14 d in vitro. Primary antibodies were applied as follows:
rabbit anti-doublecortin (DCX) (Abcam); mouse monoclonal anti-PSA-NCAM (2-2B) (Millipore Bioscience); mouse monoclonal anti-βIII tubulin (TUJ1) (Covance, 1:500); mouse monoclonal anti-MAP-2 (AP20) (Millipore Bioscience); rabbit anti-GFAP (DAKO, 1:3000); mouse monoclonal anti-GFAP (SMI-22) (Covance); mouse monoclonal anti-preoligodendroglial antigen O1 (O1) (R&D Systems); rabbit anti-β-catenin (Millipore Bioscience); rabbit anti-β-catenin (Sigma Aldrich); and rabbit anti-FLAG (Sigma Aldrich). Fluorescent-labeling Alexa Fluor 488- or 568-conjugated secondary antibodies against rabbit IgG, mouse IgG or IgM were used for detection (Invitrogen).
Western blot: Proteins were probed with the following polyclonal rabbit antibodies:
anti-nestin (Santa Cruz, H-95); anti-Dlx2 (Millipore Bioscience); anti-Wnt3 (Zymed Invitrogen); anti-frizzled (Santa Cruz H-300); anti-Neurogenin 2 (Abcam); anti-ASH1 (Millipore Bioscience); anti-β-catenin (Millipore Bioscience); anti-PARP (Santa Cruz, H-250); and anti-β-catenin [phosphoserines 33 and 37] (Zymed Invitrogen).
and the following mouse monoclonals:
anti-GSK-3β (Zymed Invitrogen); anti-NeuN (A60) (Millipore Bioscience) and anti-β-actin (Sigma Aldrich)

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad